Fuad El-Hibri and Healthcare Reform

Fuad El-Hibri serves on the Advisory Board for the Yale Healthcare Conference, a joint effort between the Yale School of Management and the Health Professional Schools at Yale University.   The 6th annual healthcare conference was held on April 9, 2010 in New Haven, CT.  The conference topic was “Re-Forming Healthcare: Excellence in a Transforming [...]

April 16, 2010  Tags: , , , , ,   Posted in: CEO, Emergent BioSolutions, Health Care, Yale University, fuad el-hibri  No Comments

Fuad el-Hibri, king of anthrax, wins an award from Ernst & Young

Marie-José Daoud
Awarded the Ernst and Young prize for Entrepreneur of the year 2009 in the Technology category for the Greater Washington region last June, Fuad El-Hibri is the CEO of Emergent Biosolutions, an American company that supplies the anthrax vaccine to the American government. He is in line for the national E&Y 2009 prize, which [...]

December 17, 2009  Tags: , , , , ,   Posted in: Biosolutions, Department of Health and Human Services, El-Hibri, Emergent BioSolutions, fuad el-hibri  No Comments

Emergent BioSolutions reacts to BARDA’s Request for Proposal cancellation

by Nick Rees on December 8, 2009
Fuad El-Hibri
The Office of the Biomedical Advanced Research and Development Authority has advised Emergent BioSolutions that while BARDA’s Request for Proposal has been canceled, Emergent is encouraged to submit a proposal for the office’s Broad Agency Announcement.
BARDA canceled the RFP for the procurement for rPA vaccines after [...]

December 15, 2009  Tags: , , , , , , ,   Posted in: BARDA, Biosolutions, CEO, Department of Health and Human Services, Emergent BioSolutions, Maryland, fuad el-hibri  No Comments

Bad News Clouds Two Bio Defense Stocks

Written by Staff and Wire Reports
Tuesday, 08 December 2009 01:28
Key news developments will affect shares of these two companies who help meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons.
The two companies which waited until late after hours on Monday to announce [...]

December 15, 2009  Tags: , , , , ,   Posted in: BARDA, Department of Health and Human Services, El-Hibri, Emergent BioSolutions, Management, biotechnology, fuad el-hibri  No Comments

STATEMENT BY FUAD EL-HIBRI, EMERGENT BIOSOLUTIONS CHAIRMAN AND CHIEF EXECUTIVE OFFICER, ON THE PASSING OF ADMIRAL WILLIAM CROWE, JR., FORMER BOARD MEMBER.

ROCKVILLE, MD, October 19, 2007— Fuad El-Hibri, chairman and chief executive officer of  Emergent BioSolutions, issued the following statement on the passing of Admiral William Crowe, Jr., who served on the company’s Board of Directors from 1998-2005.
“I was deeply saddened to learn of the passing of my dear friend and former colleague, the honorable Admiral [...]

July 15, 2009  Tags: , , , , , , ,   Posted in: Uncategorized  No Comments

Emergent Biosolutions Announces That Biothrax (Anthrax Vaccine Adsorbed) Receives Market Authorization In India

Biological E. of Hyderabad, India to serve as marketing agent for BioThrax in India
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Drugs Controller General of India (DCGI) has issued a registration certificate for BioThrax® (Anthrax Vaccine Adsorbed), which enables the marketing and sale of the vaccine in India to help prevent anthrax infection. Emergent [...]

July 13, 2009  Tags: , , , , , , , ,   Posted in: Uncategorized  No Comments

U.S. Government To Purchase Additional 14.5 Million Doses Of Biothrax® Under New Contract Valued At Up To $404 Million

New contract extends USG’s commitment to purchase BioThrax through 3Q 2011 and is a follow-on to the existing 2007, $448 million contract
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has signed a new, multi-year, firm fixed price contract with the U.S. Department of Health and Human Services (HHS) to supply an additional 14.5 million [...]

July 13, 2009  Tags: , , , , , , , ,   Posted in: Uncategorized  No Comments

Emergent Biosolutions Acquires Monoclonal Anthrax Product Candidate

Acquisition represents important addition to company’s portfolio of anthrax countermeasures
Emergent BioSolutions Inc. (NYSE: EBS) announced that today it completed the acquisition of a group of anthrax monoclonal antibodies from AVANIR Pharmaceuticals (NASDAQ:AVNR), including Avanir’s lead product candidate, AVP-21D9.
AVP-21D9 is a human monoclonal antibody product candidate that is being developed as an intravenous treatment for patients [...]

July 13, 2009  Tags: , , , , , , ,   Posted in: Uncategorized  No Comments

Emergent Biosolutions Submits Proposal In Response To Hhs’ Rfp For Development And Procurement Of A Recombinant Protective Antigen Anthrax Vaccine

The company’s submission provides the U.S. Government with the critical option to select a domestic source to meet planned procurement of 25 million doses of rPA vaccine
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has submitted a proposal in response to a request for proposal (RFP) issued by the U.S. Department of Health and [...]

July 13, 2009  Tags: , , , , , , , ,   Posted in: Uncategorized  No Comments

Emergent Biosolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate And Technology

Acquisition positions Emergent to offer the U.S. Government a domestic source for an advanced anthrax vaccine candidate to meet planned procurement of 25 million doses of rPA vaccine.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed the acquisition of all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product [...]

July 13, 2009  Tags: , , , , , , ,   Posted in: Uncategorized  No Comments